Alzheimer's disease and its progression reduce pyramidal cell gain and connectivity

Magnetoencephalography scanning provides reliable biomarkers that are sensitive to Alzheimer's disease (AD) and its progression, and informative about disease mechanisms underlying cognitive decline. In vivo assays of pyramidal cell function during cognitive processes in humans improve our understanding of AD mechanisms. The amplitude of the mismatch negativity response is progressively reduced in AD. Reduced pyramidal cell gain and connectivity underlie this neurophysiological deficit. These measures are potential biomarkers for interventional studies.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-10-01
DOI
https://doi.org/10.1002/alz.70805
Primary Topic
Neural dynamics and brain function
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Alzheimer's disease and its progression reduce pyramidal cell gain and connectivity

Melek Karadag, Michael S. Perkinton, Juliette H. Lanskey, James B. Rowe et al.
Alzheimer s & Dementia
Neural dynamics and brain function
article

Alzheimer's disease and its progression reduce pyramidal cell gain and connectivity

Melek Karadag, Michael S. Perkinton, Juliette H. Lanskey, James B. Rowe, Vanessa Raymont, Richard N. Henson, Amirhossein Jafarian, Tony Thayanandan, Andrew J. Quinn, Anna Christina Nobre, Pranay Yadav, R Williams, Ece Kocagöncü, Maarten Timmers, Krish D. Singh, Jemma Pitt, Mark W. Woolrich, Stephen L. Lowe
article en

Abstract

Magnetoencephalography scanning provides reliable biomarkers that are sensitive to Alzheimer's disease (AD) and its progression, and informative about disease mechanisms underlying cognitive decline. In vivo assays of pyramidal cell function during cognitive processes in humans improve our understanding of AD mechanisms. The amplitude of the mismatch negativity response is progressively reduced in AD. Reduced pyramidal cell gain and connectivity underlie this neurophysiological deficit. These measures are potential biomarkers for interventional studies.

Alzheimer s & DementiaVol. 21(10)
Johnson & Johnson (United States) (US), Janssen (Belgium) (BE), Eli Lilly (United States) (US), MRC Cognition and Brain Sciences Unit (GB), University of Cambridge (GB), Cambridge University Hospitals NHS Foundation Trust (GB), University of Oxford (GB), Wellcome Centre for Integrative Neuroimaging (GB), AstraZeneca (Spain) (ES), Cardiff University (GB), University of Birmingham (GB)
Openalex Percentile: Top 69%
Neural dynamics and brain function
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.